Progenics Pharma Inc: (NASD: PGNX)

$3.91

-0.11 (-2.74%)

Volume 335,774

May 22 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		3.79 - 4.15
	
		52wk Low - High
		1.41 - 11.00
	
		Previous Close
		4.02
	
		Avg. Volume
		340,928
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		205.55 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.15
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.84
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		96 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.84
                        
                            Current Quarter Estimate
                            -0.25
                        
                            Most Accurate Estimate
                            -0.25
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            -0.88
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development & commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO one hundred forty, a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine.   
Full PGNX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
PGNX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.25	-0.25	-0.84	-1.03
Number of Estimates	2	2	3	2
Low Estimate	-0.25	-0.27	-1.04	-1.10
High Estimate	-0.24	-0.24	-0.53	NA
Year Ago EPS	-0.32	-0.33	-1.02	-0.84
EPS Growth	23.44%	22.73%	17.65%	-22.62%

More PGNX Estimates

Average Earnings Estimates for PGNX

EPS Growth for PGNX

Industry Analysis

Name	Symbol	Previous Close
PROGENICS PHARM	PGNX	4.02
AETERNA ZENTARS	AEZS	2.08
ANIKA THERAPEUT	ANIK	14.45
GENTIUM SPA-ADR	GENT	8.90
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.75
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.45
ALEXION PHARMA	ALXN	102.67
ALKERMES INC	ALKS	31.98

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Salix Beats on Earnings

May 14, 2013

Salix Misses on Both Counts

Mar 05, 2013

Mixed Quarter from Salix

Nov 12, 2012

Another Delay for Salix Candidate

Sep 10, 2012

Earnings Beat for Salix, EPS View Up

Aug 13, 2012

Positive Data on Theravance Drug

Jul 11, 2012

Report for PGNX

May 10, 2013

More PGNX Zacks Commentary

Financials

EPS TTM	-0.88
Sales	14
Net Income	-34
Price/Earnings	NA
Price/Book	3.05
Price/Cash Flow	NA
Price/Sales	14.63

More PGNX Financials

News

Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index - Globenewswire

May 17, 2013

Progenics Pharmaceuticals IncCorporate Event Announcement Notice - Wall Street Horizon

May 11, 2013

Earnings Scheduled For May 10, 2013 - Benzinga

May 10, 2013

Faruqi & Faruqi, LLP Launches An Investigation Against Progenics Pharmaceuticals, Inc. (PGNX) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors - Businesswire

May 10, 2013

Progenics Pharmaceuticals Announces First Quarter 2013 Financial Results - Globenewswire

May 10, 2013

Progenics Pharmaceuticals IncCorporate Event Announcement Notice - Wall Street Horizon

May 10, 2013

Progenics Pharmaceuticals IncCorporate Event Announcement Notice - Wall Street Horizon

May 6, 2013

Progenics Pharmaceuticals to Host Conference Call to Review First Quarter 2013 Financial Results on May 10 - Globenewswire

May 6, 2013

See All News Stories on PGNX

Broker Recommendations

Current ABR	3.00
ABR (Last Week)	3.00
# of recs in ABR	4
Average Target Price	NA
Industry Rank by ABR	96 out of 265
Rank in Industry	37 out of 157

More PGNX Broker Recommendations

Day Low - High	3.79 - 4.15
52wk Low - High	1.41 - 11.00
Previous Close	4.02
Avg. Volume	340,928
Industry	MED-BIOMED/GENE
Market Cap	205.55 M
Div - Yield	0.00 - 0.00
Beta	1.15
PE (Forward)	0.00
Current Year Est.	-0.84
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.84
Current Quarter Estimate	-0.25
Most Accurate Estimate	-0.25
Earnings ESP	0.00%
Next Earnings Report Date	08-08-2013
EPS Last Year	-0.88
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Progenics Pharma Inc: (NASD: PGNX)

$3.91

-0.11 (-2.74%)

Volume 335,774

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations